CDH Investments
CDH Investments is an international alternative asset fund manager based in Hong Kong, China, with over $27 billion in assets under management. Founded in 2002 by the former private equity group of China International Capital Corporation, the firm has developed into a diversified platform that encompasses private equity, venture capital, growth capital, real assets, mezzanine financing, public equities, and wealth management. CDH Investments focuses on investing in various sectors, including consumer goods, hard technology, new energy, and healthcare. The firm is managed by a seasoned team of private equity professionals who have extensive experience in the Chinese market, enabling CDH to consistently deliver superior returns relative to its industry peers.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Rotterdam
Harbour BioMed
Series A in 2018
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.